Wakamoto Pharmaceutical Co., Ltd.

Haruhisa Hirata

Nobuyuki Suzuki

Seigo Nakaya

Ritsuko Mochida

Makoto Maeda

Yoshihiro Fukuda

Ryoki Takahashi

Yoshitami Ohashi

Takashi Shimoyama

Hirosuke Okada

Masahiko Wakasugi

Masamichi Satomi

Yuji Aiba

Seiji Negoro

Azusa Kato

Azusa Katou

Tatsuo Tozawa

Naomi Kokubo

The present invention provides a probiotics product comprising, as an effective component, lactic acid bacteria belonging topossessing high adhesiveness to mucous membrane, a high proliferation ability and a high resistance to acids, a composition for preventing and/or treating digestive tract's diseases comprising the probiotics product as an effective component and a novelstrain possessing high adhesiveness to mucous membrane, a high proliferation ability and a high resistance to acids. The lactic acid bacteria and the probiotics product and the composition for preventing and/or treating digestive tract's diseases, which contain the lactic acid bacteria as an effective component, according to the present invention can sufficiently show their probiotics functions without being easily discharged from the digestive tract and urinogenital organs.

Lactic acid bacteria-containing probiotics products

The object of the present invention is to provide a diagnostic method by whichinfection can be diagnosed at low cost without causing pain on subjects and without requiring particular equipment and which is free of cross reactivity and excellent in specificity without variation among lots as a result of the use of a single antibody facilitating the quality control and which shows good sensitivity even when a single monoclonal antibody is used. The present invention provides a monoclonal antibody which recognizescatalase as an antigen.

Monoclonal antibody hybridoma immunoassay method and diagnosis kit

A method for diagnosing Crohn's disease by detecting the presence of immunoglobulins, reactive with an amylase, in a specimen by an immunologic or enzymologic method using the amylase, and a test kit for this method.

Method and test kit for measuring immunoglobulins reactive with amylase as indication of crohn's disease

Antibiotics WAP-8294A, A.sub.1, A.sub.2, A.sub.4, AX, AX-8, AX-9 and AX-13 or pharmeceutically acceptable salts thereof produced by a strain belonging to the genus Lysobacter; a method for producing the foregoing antibiotic WAP-8294A comprising the steps of cultivating, in the culture medium, a microorganism belonging to the genus Lysobacter and having an ability of producing the antibiotic WAP-8294A to produce the antibiotic and accumulate it in the culture medium; then recovering the antibiotic; as well as an antibacterial composition comprising the antibiotic or pharmaceutically acceptable salts thereof are herein disclosed. The novel antibiotic WAP-8294A has an excellent therapeutic effect on infectious diseases developed by infection with Gram-positive bacteria, in particular, MRSA and, therefore, the antibiotic is effective for treating diseases including MRSA infectious diseases developed through infection with Gram-positive bacteria as infectious bacteria.

Antibiotic WAP-8294A, method for preparing the same and antibacterial

A novel gene coding for thermostable .beta.-galactosidase, novel recombinant DNA in which a DNA fragment containing the above gene is inserted, novel Bacillus subtilis in which the above recombinant DNA is introduced, and novel thermostable .beta.-galactosidase obtained by cultivating the above Bacillus subtilis.

Gene coding for thermostable beta-galactosidase, bacillus subtilis

Growing community of inventors

Tokyo, Japan

Haruhisa Hirata